Akero, AKRO

Why Akero Therapeutics, Inc.’s (AKRO) Stock Is Up 97.52%
Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to sell.
The Akero Therapeutics Inc Rollercoaster: What’s Behind the Latest AKRO Stock Fluctuation?
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $54 which represents a slight increase of $2.53 or 4.92% from the prior close of $51.47. The stock opened at $52.48 and touched a low of $51.
Akero Therapeutics price target raised to $109 from $42 at UBS
UBS raised the firm’s price target on Akero Therapeutics (AKRO) to $109 from $42 and keeps a Buy rating on the shares. Akero reported “strong”
Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.8% on Analyst Upgrade
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan Stanley raised their price target on the stock from $46.00 to $96.00. Morgan Stanley currently has an overweight rating on the stock.
Akero Therapeutics Stock Doubles on Liver Data
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically intended to treat MASH.
Akero Therapeutics 5.333M share Secondary priced at $48.00
The deal size was raised to $350M in common stock from $300M in common stock. JPMorgan, Morgan Stanley and Jefferies acted as joint book
Akero Therapeutic prices upsized stock offering of $350M
Clinical-stage company developing transformational treatments for patients with serious metabolic disease—Akero Therapeutics (NASDAQ:AKRO) priced of an upsized underwritten public offering of 5.33M shares at $48.
Fintel on MSN1d
B of A Securities Upgrades Akero Therapeutics (AKRO)
Fintel reports that on January 30, 2025, B of A Securities upgraded their outlook for Akero Therapeutics (NasdaqGS:AKRO) from ...
STAT1d
RFK Jr.’s confirmation hearings, MASH drugs, and a controversial obesity ad
Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
Akero Therapeutics upgraded to Buy from Neutral at BofA
BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
STAT1d
MASH drugs reach a meaningful tipping point for patients and investors
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Zacks.com on MSN2d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Akero Therapeutics Reports Positive Results from SYMMETRY Study in Recent 8-K Filing
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
GlobalData on MSN3d
Akero’s cirrhosis treatment shows promise in Phase IIb study
In subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.